

This report has been validated

Rabbit haemorrhagic disease

info

*Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:	RABBIT HEMORRHAGIC DISEASE (RHD)
*Address of laboratory	via Antonio Bianchi 7/9, 25124 Brescia (Italy)
*Tel.:	+39 030 2290617
*E-mail address:	lorenzo.capucci@izsler.it
Website:	https://www.izsler.it/chi-siamo/per-chi-e-con-chi-lavoriamo/centri-di-referenza/internazionali/oie-reference
*Name (including Title) of Head of Laboratory (Responsible Official):	Dr. Piero FRAZZI (DVM, General Director of IZSLER)
*Name (including Title and Position) of WOAH Reference Expert:	Dr. Lorenzo Capucci (BSc)
*Which of the following defines your laboratory? Check all that apply:	<input checked="" type="checkbox"/> Governmental <input type="checkbox"/> Research agency <input type="checkbox"/> Academic institution <input type="checkbox"/> Other
* <i>These questions are mandatory</i>	

TOR1

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Include all diagnostic tests performed for the specified disease/topic at your laboratory for purposes such as disease diagnosis, screening of animals for export, surveillance, etc. Do not include tests performed for quality control, proficiency testing or staff training. (Use a table as below and add further lines if needed)

Reponse : **Yes**

DIAGNOSTIC TEST	INDICATED IN WOAH MANUAL (YES/NO)	TOTAL NUMBER OF TEST PERFORMED LAST YEAR	
		NATIONALLY	INTERNATIONALLY
INDIRECT DIAGNOSTIC TESTS			
RHDV Competition ELIS	YES	458	325
RHDV2 Competition EL	YES	967	547

DIAGNOSTIC TEST	INDICATED IN WOAH MANUAL (YES/NO)	TOTAL NUMBER OF TEST PERFORMED LAST YEAR	
EBHSV Competition ELI	YES	389	150
RHDV IgA Isotype ELIS	YES	67	0
RHDV IgG Isotype ELIS	YES	35	23
RHDV IgM Isotype ELIS	YES	68	0
DIRECT DIAGNOSTIC TESTS		NATIONALLY	INTERNATIONALLY
RHDV Sandwich ELISA	YES	301	1
EBHSV Sandwich ELISA	YES	186	0
RT-PCR RHDV/RHDV2	YES	15	3
RT-PCR EBHSV	YES	25	0
Genome sequencing	YES	29	0
RT-PCR lagovirus	YES	97	0

TOR2

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAH?

If the answer to question 2 is yes, please specify the standard reference reagents available in your laboratory and whether your laboratory produces or import WOAH-approved International Standard Sera (Please add more lines if needed; the name of each Member Country should be written on a separate line) Hold-down the ctrl key to choose multiple countries from the dropdown list.

Reponse : **No**

NOTE: Currently, there are 22 laboratories that produce Standard Reference Reagents officially recognised by the WOAH for 19 diseases/pathogens. Please click the following link to the list of WOAH-approved International Standard Sera:

<http://www.oie.int/en/our-scientific-expertise/veterinary-products/reference-reagents/>

If the reagent is not listed on this page, it is NOT considered WOAH-approved. The next two questions allow you to indicate non-WOAH-approved diagnostic reagents.

- WOAH-approved SRR producing laboratory – Select your lab from list:
- Supply imported WOAH-approved SRR – Select where you import from list:

<input type="checkbox"/>	African horse sickness	Enzyme-linked immunosorbent assay	Marisa Arias Centro de Investigación en Sanidad Animal Instituto Nacional de Investigación y Tecnología Alimentarie (CISA-INIA) 28130 Valdeolmos, Madrid, España Tel: (34-91) 620.23.00 arias@inia.es
<input type="checkbox"/>	Aujeszky s disease	Enzyme-linked immunosorbent assay; Virus neutralisation	Dr Marie-Frédérique Le Potier Agence nationale de sécurité sanitaire de l'alim l'environnement et du travail (Anses) Laboratoire de Ploufragan/Plouzané/Niort Unité de Virologie Immunologie Porcines B.P. 53, 22440 Ploufragan, France Tel: +33 (0)2 96 01 62 90 marie-frederique.lepotier@anses.fr
<input type="checkbox"/>	Bluetongue	Enzyme-linked immunosorbent assay;	To be decided National Veterinary Services Laboratories USDA, Veterinary Services

		Agar gel immunodiffusion	P.O. Box 844, Ames Iowa 50010, United States of America Tel: (1-515) 337.75.51 NVSL.DVL.Heads@usda.gov https://www.aphis.usda.gov/aphis/ourfocus/ar-info-services/sa_reagents/ct_reagents
<input type="checkbox"/>	Bovine brucellosis	Indirect and Competitive enzyme-linked immunosorbent assay; Complement fixation; Agglutination; Buffered Brucella antigen tests; Fluorescence polarisation assay	Dr Adrian Whatmore Animal and Plant Health Agency New Haw, Addlestone Surrey KT15 3NB, United Kingdom Tel: (+44-1932) 35.76.10 Adrian.Whatmore@apha.gov.uk
<input type="checkbox"/>	Brucella abortus	Complement fixation; Agglutination; Buffered Brucella antigen tests; Fluorescence polarisation assay; Indirect and Competitive enzyme-linked immunosorbent assay	Dr Judith A. Stack (as above)
<input type="checkbox"/>	Brucella ovis	Complement fixation	Dr Adrian Whatmore (as above)
<input type="checkbox"/>	Classical swine fever	Virus neutralisation	Dr Helen Crooke Animal and Plant Health Agency New Haw, Addlestone Surrey KT15 3NB, United Kingdom Tel: (44-208) 026 9665 helen.crooke@apha.gov.uk
<input type="checkbox"/>	Contagious bovine pleuropneumonia	Both irradiated and non-irradiated sera are available. Please contact the Reference Laboratory for advice on their suitability for different types of serological test (complement fixation test, indirect or competitive enzyme-linked immunosorbent assay)	Dr Massimo Scacchia Istituto Zooprofilattico Sperimentale dell'Abru: "G. Caporale" Via Campo Boario, 64100 Teramo, Italy Tel: (39-0861) 33.24.05 m.scacchia@izs.it
<input type="checkbox"/>	Contagious bovine pleuropneumonia	Complement fixation test	Dr Ana Rosa Pombo Botelho Instituto Nacional de Investigação Agrária e Ve (INIAV, IP) Av. da República, Quinta do Marquês

			s/n, 2780-157 Oeiras, Portugal Tel: +351-21 440 35 14 ana.botelho@iniav.pt
<input type="checkbox"/>	Enzootic bovine leukosis	Agar gel immunodiffusion	Prof. Thomas Vahlenkamp Institute of Virology Centre for Infectious Diseases Faculty of Veterinary Medicine Leipzig University, An den Tierkliniken 29 04103 Leipzig, Germany Tel: (49-341) 97.38.201 Thomas.vahlenkamp@uni-leipzig.de
<input type="checkbox"/>	Equine infectious anaemia	Agar gel immunodiffusion	Dr Stephan Zientara UMR Virologie Anses/INRA/ENVA 23 avenue du Général de Gaulle 94703 Maison-Alfort, France Tel: 33 (0)1 43.96.72.82 s.zientara@vet-alfort.fr stephan.zientara@anses.fr
<input type="checkbox"/>	Equine influenza	Haemagglutination inhibition; single radial haemolysis	Dr Marie-Emmanuelle Behr-Gross European Directorate for the Quality of Medicines, Council of Europe 7 allée Kastner, F-67081 Strasbourg Cédex, France Tel: 33 (0)3 90.21.41.08 marie-emmanuelle.behr-gross@edqm.eu
<input type="checkbox"/>	Equine influenza	Antigens and antisera for in-vitro standardisation of vaccines	NIBSC (National Institute for Biological Standards Control), P.O. Box 1193, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QH, United Kingdom Tel: (44-1707) 65.47.53 standards@nibsc.ac.uk
<input type="checkbox"/>	Equine viral arteritis	Virus neutralisation	Dr Peter J. Timoney Maxwell H. Gluck Equine Research Center, Dept of Veterinary Science, University of Kent Lexington, Kentucky 40546-0099, United States of America Tel: (1-859) 47 57 ext. 81094 ptimoney@uky.edu
<input type="checkbox"/>	Foot and mouth disease	Enzyme-linked immunosorbent assay (antigen and antibody detection); Virus neutralisation	Dr Donald King Institute for Animal Health, Pirbright Laborator Ash Road, Pirbright, Woking, Surrey GU24 0NF, United Kingdom Tel: (44-1483) 23.24.41 donald.king@pirbright.ac.uk
<input type="checkbox"/>	Foot and mouth disease	Nonstructural protein tests	Dr Edviges Maristela Pituco Centro Panamericano de Fiebre Aftosa OPS/ON Av. President Kennedy 7778, Sao Bento Duque de Caxias, ZC 25040-004 Rio de Janeiro, Brazil Tel: (55-21) 36.61.90.64 pitucoedv@paho.org

<input type="checkbox"/>	Infectious bovine rhinotracheitis	Virus neutralisation; Enzyme-linked immunosorbent assay	Dr Stephen Valas Laboratoire de Ploufragan-Plouzané-Niort Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (Anses) 60 rue Pied de Fond, CS 28440 79024 Niort Cedex, France Tel: 33 (0)5 49.79.61.28 stephen.valas@anses.fr
<input type="checkbox"/>	Ovine and caprine brucellosis (anti-Brucella melitensis [ISaBmS])	Indirect and Competitive enzyme-linked immunosorbent assay; Fluorescence polarisation assay; Buffered Brucella antigen tests	Dr Adrian Whatmore (as above)
<input type="checkbox"/>	Peste des petits ruminants	Enzyme-linked immunosorbent assay	Dr Arnaud Bataille CIRAD-Bios, Campus international de Baillargu TA A-15/G, B.P. 5035, 34398 Montpellier Cedex Tel: 33 (0)4 67 59 37 98 arnaud.bataille@cirad.fr
<input type="checkbox"/>	Rabies	Fluorescent antibody virus neutralisation	Dr Florence Cliquet Anses Nancy, Laboratoire d'études sur la rage des animaux sauvages, Domaine de Pixérécourt BP 9, 54220 Malzéville, France Tel: 33 (0)3 83.29.89.50 florence.cliquet@anses.fr
<input type="checkbox"/>	Swine vesicular disease	Enzyme-linked immunosorbent assay (antibody detection); Virus neutralisation	Dr Donald King The Pirbright Institute, Ash Road, Pirbright, Woking, Surrey, GU24 0NF, United Kingdom Tel: (44-1483) 23.24.41 donald.king@pirbright.ac.uk
<input type="checkbox"/>	Trichinellosis	Enzyme-linked immunosorbent assay	Dr Maria Angeles Gomez Morales Istituto Superiore di Sanita, Laboratorio di Parasitologia e Malattie Tropicali Viale Regina Elena 299, 00161 Roma, Italy Tel: +390-6 49.90.23.04 mariaangeles.gomezmorales@iss.it

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TESTING	PRODUCED/ IMPORTED	QUANTITY SUPPLIED NATIONWIDE (ML, MG)	QUANTITY SUPPLIED AT INTERNATIONAL LEVEL (ML, MG)	NAME OF BENEFICIARY COUNTRIES
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> <10mL <input type="checkbox"/> 10-100mL <input type="checkbox"/> 100-500mL <input type="checkbox"/> >500mL	<input type="checkbox"/> <10mL <input type="checkbox"/> 10-100mL <input type="checkbox"/> 100-500mL <input type="checkbox"/> >500mL	AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAH Members?
 If the answer to question 3 is yes, please specify the standard reference reagents and/or other diagnostic reagents available in your laboratory (Please add more lines if needed)

Reponse : **Yes**

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOAH MEMBER COUNTRIES	CO-OPERATIVE REGION
RHDV serological	c-ELISA	produced	1 kit	10 kits	4	AFRICA AMERICAS ASIA EUROPE MIDDLE EAST
EBHSV serological	c-ELISA	produced	2 kits	15 kits	3	AFRICA AMERICAS ASIA EUROPE MIDDLE EAST
RHDV/ EBHSV viral	MAbs sandwich ELISA	produced	14 kits	11 kits	3	AFRICA AMERICAS ASIA EUROPE MIDDLE EAST
RHDV 2 serological	c-ELISA	produced	1 kit	16 kits	6	AFRICA AMERICAS ASIA EUROPE MIDDLE EAST
RHDV/ RHDV 2	MAbs sandwich ELISA	produced	0	4 kits	1	AFRICA AMERICAS ASIA EUROPE MIDDLE EAST

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOAH MEMBER COUNTRIES	CO-OPERATIVE
						ME
						AI
						AI
Monoclonal antibody	Immunohistochemistry	produced	0	2mg/2ml	1	AS PE EU ME
						AI
						AI
Reference positive	PCR	provided	0	1 panel	2	AS PE EU ME
						AI
						AI
Positive and negative	Serological ELISA	provided	0	1 panel	2	AS PE EU ME
						AI
						AI
Positive	RT-PCR	provided	0	1	1	AS PE EU ME

4. Did your laboratory produce vaccines?

Reponse : **Yes**

5. Did your laboratory supply vaccines to WOAH Members?

If the answer is yes, please provide information

Reponse : **No**

VACCINE NAME	AMOUNT SUPPLIED NATIONALLY (ML, MG) (INCLUDING FOR OWN USE)	AMOUNT SUPPLIED NATIONALLY (ML, MG)	NAME OF RECIPIENT WOAH MEMBERS
Your message...	<input type="text"/>	<input type="text"/>	AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA

TOR3

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

Reponse : **No**

7. Did your laboratory validate diagnostic methods according to WOAH Standards for the designated pathogen or disease?

If the answer is yes to at least one of the previous two questions, please provide information on where detailed information can be obtained (e.g. website, publication or postal address where the report may be requested)

Reponse : **No**

NAME OF THE NEW TEST OR DIAGNOSTIC METHOD DEVELOPED	DESCRIPTION AND REFERENCES (PUBLICATION, WEBSITE, ETC.)
Your message...	Your message...

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

If the answer is yes to at least one of the previous two questions, please provide information on where the detailed information can be obtained (e.g. website, publication or postal address where the report may be requested)

Reponse : **No**

9. Did your laboratory validate vaccines according to WOAH Standards for the designated pathogen or disease?

If the answer is yes to at least one of the previous two questions, please provide information on where the detailed information can be obtained (e.g. website, publication or postal address where the report may be requested)

Reponse : **No**






NAME OF THE NEW VACCINE DEVELOPED	DESCRIPTION AND REFERENCES (PUBLICATION, WEBSITE, ETC.)
Your message...	Your message...

TOR4

10. Did your laboratory carry out diagnostic testing for other WOAH Members?

If the answer is yes, please provide details using the appropriate box (indicate the number of samples by shipments received during last year)

Reponse : **Yes**

NAME OF WOAH MEMBER COUNTRY SEEKING ASSISTANCE	DATE (MONTH)	NO. SAMPLES RECEIVED FOR PROVISION OF DIAGNOSTIC SUPPORT	NO. SAMPLES RECEIVED FOR PROVISION OF CONFIRMATORY DIAGNOSES
AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA	 14/06/2022	40	0
AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA	 18/02/2022	0	2
AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA	 01/06/2022	15	0
GRENADA GUAM GUATEMALA GUINEA GUINEA-BISSAU	 11/02/2022	44	0
AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA	 05/04/2022	4	0

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAH Member?

If the answer is yes, please provide details using the following table (indicate which means was used to provide the assistance: remote, in loco, etc.)

Reponse : **Yes**

NAME OF THE WOAH MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA	To give information on the epidemiology and diagnosis of	Email and analyses of samples
AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA	Provision of the protocol for RNA extraction and RT-PCR	Emails
AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA	revision of the protocol for RNA extraction and RT-PCR	Emails

NAME OF THE WOAH MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA	Provision of the protocol for RNA extraction and RT-PCR	Emails
AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA	Provision of the protocol for RNA extraction and RT-PCR	Emails
AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA	To give interpretation of the epidemiological meaning of	Emails

TOR5

12. Did your laboratory participate in international scientific studies in collaboration with WOAH Members other than the own?

If the answer is yes, please provide details using the suggested table Hold-down the ctrl key to choose multiple countries from the dropdown list.

Reponse : **Yes**

TITLE OF THE STUDY	DURATION	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAH MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
PRIM	3 years	i) To monitor	1.CIBIO/InBIO-UP Portugal	AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA
Study	2 years	To verify the	CITA, Zaragoza, SPAIN	AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA
Enferme	2 years	To study the	El Instituto de las Ciencias de	AFGHANISTAN AMERICAN SAMOA ALBANIA ANTIGUA AND BARBUDA ALGERIA

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAH?

*Regulatory research needs = a gap in knowledge that could help in setting/updating standard(s) in the Terrestrial and Aquatic Codes and Manuals

Click here !

TOR6

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Reponse : **Yes**

IF THE ANSWER IS YES,
PLEASE PROVIDE
DETAILS OF THE DATA
COLLECTED:

We analyse the
genomic and
antigenic

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Reponse : **Yes**

IF THE ANSWER IS YES,
PLEASE PROVIDE
DETAILS OF THE DATA
COLLECTED:

Epidemiological
data obtained from
the examination of
samples received

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

5

1) ASIN JAVIER, DANIEL REJMANEK, DEANA L. CLIFFORD, ANDREA B. MIKOLON, EILEEN E. HENDERSON, AKINYI O. NYAKOKE, MELISSA MACÍAS

b) International conferences:

6

1) BARATELLI M., MOLIST-BADIOLA J., PUIGREDON-FONTANET A., PASCUAL M., BOIX O., MORA-IGUAL E., WOODWARD M., LAZZAZZA A., CARUSO L. 2021

c) National conferences:

0

Your message...

d) Other (Provide website address or link to appropriate information):

0

Your message...

TOR7

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAH Members?

If the answer is yes, please provide the total number of trained persons for each of the following categories:

Reponse : **Yes**

a) Technical visit

2

b) Seminars

1

c) Hands-on training courses

0

d) Internships (>1 month)

1

Please provide details (specify the type of training provided using the letter ranked above)

TYPE OF TECHNICAL TRAINING PROVIDED (A, B, C OR D)	COUNTRY OF ORIGIN OF THE EXPERT(S) PROVIDED WITH TRAINING	NO. PARTICIPANTS FROM THE CORRESPONDING COUNTRY
a	TUNISIA	1
a	ALGERIA	3
d	PORTUGAL/SPAIN	1
b	PHILIPPINES	30

TOR8

18. Does your laboratory have a Quality Management System?

Reponse : **Yes**

QUALITY MANAGEMENT SYSTEM ADOPTED	CERTIFICATE SCAN (PDF, JPG, PNG FORMAT)	
UNI CEI ENISO/IEC 170:	PDF	<i>Fichier soumis : C:\fakepath\CERTIFICATO-DI-ACCREDITAMENTO-2.pdf</i>

19. Is your quality management system accredited?

If the answer is yes, please provide information

Reponse : **Yes**

TEST FOR WHICH YOUR LABORATORY IS ACCREDITED	ACCREDITATION BODY
RT_PCR	ILAC MRA, ACCREDIA
Serological Competitive	ILAC MRA, ACCREDIA
Serological Competitive	ILAC MRA, ACCREDIA
Virological sandwich M.	ILAC MRA, ACCREDIA
Immunohistochemistry	ILAC MRA, ACCREDIA
Electron Microscopy ne	ILAC MRA, ACCREDIA

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

If the answer is yes, please provide details

Reponse : **Yes**

The laboratory works according to the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4 and the WHO Laboratory Biosafety Manual. A risk analysis approach was adopted to manage the biological risks of specific agents aimed at biosecurity in veterinary laboratories and animal facilities

TOR9

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAHP?

If the answer is yes, please provide a list of scientific meetings using the appropriate table

Reponse : **No**

NATIONAL/ INTERNATIONAL	TITLE OF EVENT	CO- ORGANISER	DATE (MM/YY)	LOCATION	NO. PARTICIPANTS
<input type="checkbox"/> International <input type="checkbox"/> National	Your m		gg/mm/aaaa		

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAHP?

If the answer is yes, please provide a list of scientific meetings using the appropriate table

Reponse : **Yes**

TITLE OF EVENT	DATE (MM/YY)	LOCATION	ROLE (SPEAKER, PRESENTING POSTER, SHORT COMMUNICATIONS)	TITLE OF THE WORK PRESENTED
Meeting between Philippines	28/01/2022	VDC on	Speaker	1. Lagovir US
Technical questions on rabbit	10/03/2022	VDC on	Speaker	1.RABBIT HAEMO

TOR10

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

Reponse : **Not applicable (Only WOAHP Reference Laboratory designated for the disease)**

24. Are you a member of a network of WOAHP Reference Laboratories designated for the same pathogen?

If the answer is yes, please provide details using the following table

Reponse : **Not applicable (Only WOAHP Reference Laboratory designated for the disease)**

PURPOSE OF THE PROFICIENCY TESTS: ¹	ROLE OF YOUR REFERENCE LABORATORY (ORGANISER/ PARTICIPANT)	NO. PARTICIPANTS	PARTICIPATING WOAHP REF. LABS/ ORGANISING WOAHP REF. LAB.
Your message...			Your message...

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen?

If the answer is yes, please provide details using the following table

Reponse : **Not applicable (Only WOAHP Reference Laboratory designated for the disease)**

PURPOSE OF THE PROFICIENCY TEST	ROLE OF YOUR REFERENCE LABORATORY (ORGANISER/PARTICIPANT)	NO. PARTICIPATING LABORATORIES	PARTICIPATING WOAHP REF. LABS/ ORGANISING WOAHP REF. LAB.

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

If the answer is yes, please provide details using the following table

Reponse : **Not applicable (Only WOAHP Reference Laboratory designated for the disease)**

TITLE OF THE PROJECT OR CONTRACT	SCOPE	NAME(S) OF RELEVANT WOAHP REFERENCE LABORATORIES
Your message...	Your message...	Your message...

TOR11

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen?

If the answer is yes, please provide details using the table provided

Reponse : **Yes**

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/fr/notre-expertise-scientifique/laboratoires-de-reference/test-de-competence> see point 1.3

PURPOSE FOR INTER-LABORATORY TEST COMPARISONS ¹	ROLE OF YOUR REFERENCE LABORATORY (ORGANIZER/PARTICIPANT)	NO. PARTICIPATING LABORATORIES	REGION(S) OF PARTICIPATING WOAHP MEMBER COUNTRIES
We prepared and distributed a panel of positive samples	Organizer	3	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

TOR12

28. Did your laboratory place expert consultants at the disposal of WOAHP?

If the answer is yes, please provide a list of details (attendance at, for example WOAHP Commission meetings, ad hoc Group meetings, review of WOAHP Standards, responding to specific technical queries from WOAHP, technical papers on diagnostic test procedures or vaccine production, etc.)

Reponse : **Yes**

KIND OF CONSULTANCY	LOCATION	SUBJECT (FACULTATIVE)
Preparation of the OIE Case Definition for Rabbit	On site, by email	Contribution to the preparation of technical report with the case
Revision of OIE Standards. Chapter 2.7.2 of the WOAHP	On site, by email	We changes table 1 to make it coherent with the "RHD case

29. Additional comments regarding your report:

(For example, please explain why there was little or no activity in the reporting period or any other difficulty encountered in fulfilling the Terms of Reference, if relevant.)

Reponse : **Yes**

During 2022 the laboratory has applied both nationally and internationally the specific direct and indirect tests (MAbsELISA and RT PCR for antigen detection, cELISA and isotype_ELISAs for antibodies detection) specifically developed for RHDV2. Following the epidemic occurrence of RHDV2 in North and Central America we still continued to collaborate and support American colleagues for